Acelyrin (NASDAQ:SLRN) Receives “Neutral” Rating from HC Wainwright

Acelyrin (NASDAQ:SLRN)‘s stock had its “neutral” rating restated by research analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They presently have a $8.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 97.04% from the company’s current price.

Other equities analysts also recently issued research reports about the company. Morgan Stanley lowered their price target on Acelyrin from $13.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Monday, August 19th. Wells Fargo & Company boosted their target price on Acelyrin from $13.00 to $15.00 and gave the stock an “overweight” rating in a report on Wednesday, October 16th. Finally, Piper Sandler decreased their price objective on shares of Acelyrin from $68.00 to $20.00 and set an “overweight” rating on the stock in a report on Wednesday, August 14th.

Acelyrin Price Performance

Acelyrin stock opened at $4.06 on Wednesday. The company’s 50-day moving average is $5.29 and its 200-day moving average is $5.02. The firm has a market capitalization of $407.34 million, a PE ratio of -1.65 and a beta of 1.63. Acelyrin has a fifty-two week low of $3.36 and a fifty-two week high of $8.89.

Institutional Trading of Acelyrin

Several institutional investors have recently added to or reduced their stakes in SLRN. Millennium Management LLC lifted its holdings in shares of Acelyrin by 15.7% during the second quarter. Millennium Management LLC now owns 4,642,056 shares of the company’s stock worth $20,471,000 after buying an additional 628,528 shares in the last quarter. Blue Owl Capital Holdings LP increased its position in Acelyrin by 3.5% during the second quarter. Blue Owl Capital Holdings LP now owns 2,926,028 shares of the company’s stock worth $12,904,000 after acquiring an additional 100,000 shares during the period. Geode Capital Management LLC raised its stake in Acelyrin by 30.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,651,614 shares of the company’s stock worth $8,144,000 after purchasing an additional 388,631 shares in the last quarter. State Street Corp boosted its holdings in Acelyrin by 10.0% in the 3rd quarter. State Street Corp now owns 1,273,096 shares of the company’s stock valued at $6,276,000 after purchasing an additional 116,094 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Acelyrin by 81.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 609,678 shares of the company’s stock worth $3,006,000 after purchasing an additional 273,604 shares in the last quarter. 87.31% of the stock is currently owned by institutional investors.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.